2026-01-20 - Analysis Report
**Company Overview**
Amgen is a biotechnology company that develops, manufactures, and distributes human therapeutics for serious medical conditions.

**Return Rate Comparison**
* Review stock: AMGN, Cumulative return: 71.01%
* Comparison stock (S&P 500, VOO): Cumulative return: 93.30%
* Divergence (max: 26.40, min: -46.20, current: -22.30, relative divergence: 32.90%)

**Alpha, Beta Analysis**
| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2016-2018  | 14.0% | 14.6% | 10.0% | 1.1 | 104.8B |
| 2017-2019  | 41.0% | 12.4% | 23.0% | 0.9 | 129.8B |
| 2018-2020  | 8.0% | 17.7% | -13.0% | 0.8 | 123.8B |
| 2019-2021  | 15.0% | 17.7% | -28.0% | 0.8 | 121.1B |
| 2020-2022  | 15.0% | 15.5% | 17.0% | 0.6 | 141.4B |
| 2021-2023  | 19.0% | 15.3% | 19.0% | 0.4 | 155.1B |
| 2022-2024  | 12.0% | 21.0% | -8.0% | 0.4 | 140.3B |
| 2023-2025  | 38.0% | 21.0% | -24.0% | 0.5 | 176.2B |

**Recent Stock Price Fluctuations**
* Close: $330.41
* Last-market change: $0.12 (0.04% increase)
* 5-day SMA: $327.85
* 20-day SMA: $329.14
* 60-day SMA: $324.51

**RSI, PPO, Expected_Return Analysis**
* Market Risk Indicator (MRI): 0.80
* RSI: 47.80
* PPO: -0.04
* Hybrid Signal: Buy (Cash 0%)
* Risk Level: Medium (MRI 0.80)
* Recent (20 days) relative divergence change: 4.00 (+): improving
* 7-day Rank change: 47 (+): rank up
* 7-day Dynamic Expected Return change: 0.50 (+): improving
* Expected Return (%): -2.00%

**Recent News & Significant Events**
* [2026-01-19] Allstate Corp Has $5.54 Million Stock Position in Amgen Inc. $AMGN - MarketBeat
* [2026-01-18] Amgen Inc. (NASDAQ:AMGN) is largely controlled by institutional shareholders who own 80% of the company - Yahoo Finance
* [2026-01-19] Should You Buy, Sell or Hold J&J Stock Ahead of Q4 Results? - The Globe and Mail
* [2026-01-07] Stocks making the biggest moves midday: Deckers Outdoor, Amgen, Western Digital, Ventyx Biosciences & more - CNBC
* [2026-01-16] Is Amgen (AMGN) Still Attractive After A 26% One Year Share Price Gain - simplywall.st
* [2026-01-19] Royal Fund Management LLC Cuts Holdings in Amgen Inc. $AMGN - MarketBeat

**Analyst Opinions**
* Analyst Consensus:
	+ Key: Buy
	+ Mean (1=StrongBuy~5=Sell): 2.34 (~Buy)
	+ Opinions: 27
	+ Target Price (avg/high/low): 331.59 / 425.00 / 180.00

**Recent Earnings Analysis**
| Date | EPS | Revenue |
|------|-----|---------|
| 2025-11-05 | 5.98 | $9.56B |
| 2025-08-06 | 2.66 | $9.18B |
| 2025-05-02 | 3.22 | $8.15B |
| 2024-10-31 | 5.27 | $8.50B |
| 2025-11-05 | 5.27 | $8.50B |

The earnings per share (EPS) has been increasing, but the revenue growth has been steady. There is a need for revenue growth to sustain the business.

**Financial Information**
**Revenue and Profitability**
| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $9.56B | 67.75% |
| 2025-06-30 | $9.18B | 67.20% |
| 2025-03-31 | $8.15B | 63.58% |
| 2024-12-31 | $9.09B | 65.75% |
| 2024-09-30 | $8.50B | 61.07% |

The revenue has been steady, and the profit margin has been increasing. The company's profitability is improving.

**Capital and Profitability**
| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $9.62B | 33.43% |
| 2025-06-30 | $7.43B | 19.28% |
| 2025-03-31 | $6.21B | 27.87% |
| 2024-12-31 | $5.88B | 10.67% |
| 2024-09-30 | $7.53B | 37.60% |

The equity has been increasing, and the return on equity (ROE) has been improving. The company's capital is growing.

**Comprehensive Analysis (Summary of previous items)**
Amgen is a biotechnology company with a strong EPS growth and steady revenue. The profit margin has been increasing, and the company's profitability is improving. The equity has been increasing, and the ROE has been improving. The analyst consensus is Buy, with a target price of $331.59. The recent news and significant events suggest that the company is attractive, but there are also some concerns. The comprehensive analysis suggests that Amgen is a good investment opportunity, but it's essential to consider individual circumstances before making a decision.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.